NOVAVAX INC (NVAX) Stock Fundamental Analysis
NASDAQ:NVAX - US6700024010 - Common Stock
7.84 USD
+0.21 (+2.75%)
7.92 USD
+0.08 (+1.02%)
Taking everything into account, NVAX scores 4 out of 10 in our fundamental rating. NVAX was compared to 547 industry peers in the Biotechnology industry. There are concerns on the financial health of NVAX while its profitability can be described as average. NVAX has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
NVAX had positive earnings in the past year.
In the past year NVAX has reported a negative cash flow from operations.
In the past 5 years NVAX always reported negative net income.
In the past 5 years NVAX reported 4 times negative operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 31.64%, NVAX belongs to the best of the industry, outperforming 98.54% of the companies in the same industry.
The Return On Equity of NVAX (1123.78%) is better than 99.82% of its industry peers.
NVAX's Return On Invested Capital of 30.55% is amongst the best of the industry. NVAX outperforms 98.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 31.64% | ||
| ROE | 1123.78% | ||
| ROIC | 30.55% |
ROA(3y)-23.82%
ROA(5y)-33.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 39.20%, NVAX belongs to the best of the industry, outperforming 97.81% of the companies in the same industry.
Looking at the Operating Margin, with a value of 33.97%, NVAX belongs to the top of the industry, outperforming 98.00% of the companies in the same industry.
The Gross Margin of NVAX (88.30%) is better than 90.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.97% | ||
| PM (TTM) | 39.2% | ||
| GM | 88.3% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
NVAX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
NVAX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for NVAX has been increased compared to 5 years ago.
NVAX has a worse debt/assets ratio than last year.
2.2 Solvency
NVAX has an Altman-Z score of -1.82. This is a bad value and indicates that NVAX is not financially healthy and even has some risk of bankruptcy.
NVAX has a Altman-Z score (-1.82) which is comparable to the rest of the industry.
NVAX has a Debt/Equity ratio of 5.93. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 5.93, NVAX is not doing good in the industry: 82.70% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.93 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.82 |
ROIC/WACC3.1
WACC9.86%
2.3 Liquidity
NVAX has a Current Ratio of 2.36. This indicates that NVAX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.36, NVAX is doing worse than 70.49% of the companies in the same industry.
A Quick Ratio of 2.34 indicates that NVAX has no problem at all paying its short term obligations.
NVAX's Quick ratio of 2.34 is on the low side compared to the rest of the industry. NVAX is outperformed by 68.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.36 | ||
| Quick Ratio | 2.34 |
3. Growth
3.1 Past
NVAX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 171.01%, which is quite impressive.
The Revenue has grown by 9.22% in the past year. This is quite good.
Measured over the past years, NVAX shows a very strong growth in Revenue. The Revenue has been growing by 105.31% on average per year.
EPS 1Y (TTM)171.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-37.37%
Revenue 1Y (TTM)9.22%
Revenue growth 3Y-15.89%
Revenue growth 5Y105.31%
Sales Q2Q%-42.42%
3.2 Future
NVAX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.77% yearly.
NVAX is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -9.90% yearly.
EPS Next Y239.6%
EPS Next 2Y46.05%
EPS Next 3Y21.97%
EPS Next 5Y17.77%
Revenue Next Year57.88%
Revenue Next 2Y-15.56%
Revenue Next 3Y-29.4%
Revenue Next 5Y-9.9%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 4.00, the valuation of NVAX can be described as very cheap.
Based on the Price/Earnings ratio, NVAX is valued cheaper than 98.72% of the companies in the same industry.
NVAX is valuated cheaply when we compare the Price/Earnings ratio to 27.24, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 35.70, which means the current valuation is very expensive for NVAX.
Based on the Price/Forward Earnings ratio, NVAX is valued cheaply inside the industry as 90.71% of the companies are valued more expensively.
NVAX's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 22.81.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4 | ||
| Fwd PE | 35.7 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, NVAX is valued cheaper than 99.09% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 1.3 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as NVAX's earnings are expected to grow with 21.97% in the coming years.
PEG (NY)0.02
PEG (5Y)N/A
EPS Next 2Y46.05%
EPS Next 3Y21.97%
5. Dividend
5.1 Amount
NVAX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
7.84
+0.21 (+2.75%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners57.9%
Inst Owner Change2.85%
Ins Owners0.41%
Ins Owner Change18.95%
Market Cap1.27B
Analysts74.29
Price Target14.86 (89.54%)
Short Float %28.64%
Short Ratio6.84
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)483.55%
Min EPS beat(2)306.88%
Max EPS beat(2)660.22%
EPS beat(4)3
Avg EPS beat(4)228.68%
Min EPS beat(4)-58.31%
Max EPS beat(4)660.22%
EPS beat(8)5
Avg EPS beat(8)86.86%
EPS beat(12)7
Avg EPS beat(12)38.5%
EPS beat(16)7
Avg EPS beat(16)-17.35%
Revenue beat(2)2
Avg Revenue beat(2)74.3%
Min Revenue beat(2)58.52%
Max Revenue beat(2)90.08%
Revenue beat(4)4
Avg Revenue beat(4)40.88%
Min Revenue beat(4)2.61%
Max Revenue beat(4)90.08%
Revenue beat(8)5
Avg Revenue beat(8)18.46%
Revenue beat(12)7
Avg Revenue beat(12)18.88%
Revenue beat(16)7
Avg Revenue beat(16)2.76%
PT rev (1m)-3.77%
PT rev (3m)-12.57%
EPS NQ rev (1m)-24.9%
EPS NQ rev (3m)-42.87%
EPS NY rev (1m)-5.2%
EPS NY rev (3m)-8.08%
Revenue NQ rev (1m)-11.87%
Revenue NQ rev (3m)80.37%
Revenue NY rev (1m)4.06%
Revenue NY rev (3m)15.48%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4 | ||
| Fwd PE | 35.7 | ||
| P/S | 1.18 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 33.84 | ||
| P/tB | N/A | ||
| EV/EBITDA | 1.3 |
EPS(TTM)1.96
EY25%
EPS(NY)0.22
Fwd EY2.8%
FCF(TTM)-3.91
FCFYN/A
OCF(TTM)-3.88
OCFYN/A
SpS6.64
BVpS0.23
TBVpS-0.46
PEG (NY)0.02
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 31.64% | ||
| ROE | 1123.78% | ||
| ROCE | 38.67% | ||
| ROIC | 30.55% | ||
| ROICexc | 86.37% | ||
| ROICexgc | 130.29% | ||
| OM | 33.97% | ||
| PM (TTM) | 39.2% | ||
| GM | 88.3% | ||
| FCFM | N/A |
ROA(3y)-23.82%
ROA(5y)-33.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.81
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.93 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.55 | ||
| Cap/Depr | 11.6% | ||
| Cap/Sales | 0.44% | ||
| Interest Coverage | 18.14 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.36 | ||
| Quick Ratio | 2.34 | ||
| Altman-Z | -1.82 |
F-Score6
WACC9.86%
ROIC/WACC3.1
Cap/Depr(3y)158.98%
Cap/Depr(5y)408.8%
Cap/Sales(3y)4.02%
Cap/Sales(5y)5.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)171.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-37.37%
EPS Next Y239.6%
EPS Next 2Y46.05%
EPS Next 3Y21.97%
EPS Next 5Y17.77%
Revenue 1Y (TTM)9.22%
Revenue growth 3Y-15.89%
Revenue growth 5Y105.31%
Sales Q2Q%-42.42%
Revenue Next Year57.88%
Revenue Next 2Y-15.56%
Revenue Next 3Y-29.4%
Revenue Next 5Y-9.9%
EBIT growth 1Y228.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year293.39%
EBIT Next 3Y13.43%
EBIT Next 5YN/A
FCF growth 1Y13.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y3.53%
OCF growth 3YN/A
OCF growth 5YN/A